Oct 7, 4:13 PM ET
Hims & Hers appointed Jonathan M. Franklin as principal accounting officer, effective October 9, 2026, replacing Irene Becklund, who resigned from the role. Franklin started as chief accounting officer on October 5, 2026, and joins from Rivian Automotive, where he was a vice president and corporate controller.
- Jonathan M. Franklin, 43, started as chief accounting officer on October 5, 2026, and becomes principal accounting officer on October 9, 2026.
- Franklin's compensation includes a $425,000 base salary, a $150,000 signing bonus, and restricted stock units with a $3,000,000 grant value.
- Irene Becklund's resignation as principal accounting officer is effective alongside the appointment; she will advise the company under an agreement through July 10, 2027.
Read the filing on SEC.gov ↗
Aug 10, 4:08 PM ET
Hims & Hers reported second quarter 2026 revenue of $753.2 million, up 38% from a year earlier, and raised its full-year 2026 revenue guidance to $3.1 billion to $3.3 billion. The company swung to a net loss of $86.3 million from net income of $42.5 million in the prior-year quarter, and Adjusted EBITDA fell to $60.3 million from $82.2 million, so shareholders face higher revenue alongside lower profit.
- Q2 2026 revenue was $753.2 million, up 38% year-over-year; subscribers reached 2,891 thousand, up 19%
- Net loss was $86.3 million in Q2 2026 versus net income of $42.5 million in Q2 2025; gross margin fell to 64% from 76%
- Adjusted EBITDA was $60.3 million versus $82.2 million a year earlier; Free Cash Flow was $(68.2) million
- Full-year 2026 revenue guidance raised to $3.1 billion to $3.3 billion; Adjusted EBITDA guidance set at $275 million to $325 million
Read the filing on SEC.gov ↗
Jul 17, 4:13 PM ET
Hims & Hers Health said Chief Accounting Officer and Principal Accounting Officer Irene Becklund will resign effective October 9, 2026, and she has said the decision is not tied to any disagreement over accounting or financial reporting. The company will retain her in an advisory role from October 10, 2026 through July 10, 2027, which gives it continuity during the transition of its accounting leadership.
- Irene Becklund informed the company of her resignation on July 13, 2026, effective October 9, 2026.
- Becklund has been Chief Accounting Officer since April 2025 and Principal Accounting Officer since November 2021.
- She has stated the resignation is not the result of any dispute over accounting principles, practices, or financial statements.
- An advisory agreement effective October 10, 2026 keeps her supporting the company until July 10, 2027.
Read the filing on SEC.gov ↗
Jul 1, 5:02 PM ET
Hims & Hers subsidiaries XeCare LLC and Apostrophe Pharmacy LLC entered a Master Receivables Purchase Agreement with JPMorgan Chase Bank on July 1, 2026, allowing them to sell eligible receivables for cash, subject to a $400 million facility limit. The company also agreed to guarantee the sellers' performance under the agreement, though not the collectability of the receivables, and amended its credit agreement to permit the arrangement.
- Facility limit for eligible receivables is $400 million, with an initial term of 364 days that may be extended.
- The company guarantees the sellers' performance under the agreement but not receivable collectability or seller creditworthiness.
- Amendment No. 4 to the Revolving Credit and Guaranty Agreement, dated June 26, 2026, adds a $400 million debt basket for this arrangement.
- The filing does not disclose the purchase discount or any financial results tied to the arrangement.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.